Monday, 18 Jun 2018

You are here

Therapeutic Update: 5 Questions on Sirukumab FDA Hearing

Therapeutic updates are periodic reports that feature commentary, insight and review from leading experts on advances in therapeutics in rheumatology. These updates may feature new drug approvals or indications; product label or safety updates, new important clinical trial results, new treatment guidelines or disease management reviews. 

In this Therapeutic Update Drs. Cush and Gibofsky answer 5 questions about the August 2, 2017 FDA Arthritis Advisory Committee meeting that reviewed the NDA for sirukumab use in rheumatoid arthritis. While the panel unanimously (13-0) acknowledged the efficacy of sirukumab, they ultimately voted against (1-12) the approval of sirukumab, pointing to safety concerns and the data showing a higher number of in all-cause mortalities in sirukumab treated patients.  

 

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

a great discussion on FDA approach.Why not do one on Romosozumab which -in contrast-is both first in class and phenomenally effective.Tony Russell

More Like This

High Biologic Blood Levels Increases the Risk of Infections in RA

A big concern of most is the risk of infection with use of tumour necrosis factor inhibitor (TNFi) and biologic drugs.  While studied in both trials and in post-marketing studies, it is unknown if infection risk is dose-dependent.

In abstract OP0229 UK researchers have shown high biologic blood levels are associates with an increased risk of total infections in RA, but not serious infetions.

Biosimilar Data at #EULAR2018

Biosimilars are here, and more are being registered all the time, so I was really interested in the biosimilar data at the meeting.

Abbvie Highlights Upadacitinib Trials at EULAR18

Abbvie press releases feature the results from 3 new trials to be presented during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe rheumatoid arthritis.

Vedolizumab Implicated in Exacerbations of SpA in IBD Patients

Beloved by gastroenterologist for treatment of inflammatory bowel disease (IBD), α4β7 integrin receptor vedolizumab (VDZ) has probably caught attention of many rheumatologist since the time it entered the market; largely for what it won't do for inflammatory arthritis.

JAK Inhibition in Autoinflammatory Syndromes Interferonopathies

While many autoinflammatory syndromes are driven and managed with select inhibition of IL-1, IL-18 or IL-6, a subset are driven by type I interferon and are referred to as interferonopathies. These monogenic IFN–mediated disorders present in infancy with fevers, systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality.